Comorbidities, Dosing Issues, Polypharmacy, and Adverse Effects in Prostate Cancer
The goal of this initiative is to increase awareness, knowledge, and competence in the need for culturally sensitive, evidence-based, guideline recommended approaches for the treatment of prostate cancer in Black patients.
Provided by the National Comprehensive Cancer Network in partnership with The France Foundation
This program is designed to meet the educational needs of oncologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment and management of patients with breast and prostate cancers.
Following this activity, participants should be able to:
- Select appropriate therapy based on evidence-based guidance and individual patient characteristics and needs
- Describe comorbidities that are particularly prevalent in Black patients, drug-drug interactions, dosing considerations, and treatment side effects
Sandy Srinivas, MD
Professor of Medicine (Oncology)
Clinical Research Leader GU Oncology
Samuel L. Washington III, MD, MAS
Assistant Professor of Urology; Epidemiology & Biostatistics
Goldberg-Benioff Endowed Professorship in Cancer Biology
HDFCCC Prostate Cancer Program Community Outreach and Engagement Liaison
Associate Chair of Diversity, Equity, and Inclusion; Department of Urology, UCSF
University of California, San Francisco
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Sandy Srinivas, MD
AVEO Pharmaceuticals, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Seagen Inc.: Grant/Research Support
Samuel L. Washington III, MD, MAS
ConcertAI: Grant/Research Support
NCCN and The France Foundation Staff Disclosures
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.50 contact hour.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until March 31, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 0.50 AAPA Category 1 CME credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing